Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?
AUTOR(ES)
Chauffaille, Maria de Lourdes L.F.
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2017-09
RESUMO
Documentos Relacionados
- Monitoring imatinib plasma concentrations in chronic myeloid leukemia
- Standards for the diagnosis and treatment of chronic myeloid leukemia
- Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
- Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
- The role of natural killer cells in chronic myeloid leukemia